Clinical trials: Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) followed by glofitamab monotherapy treatment regimen (Cohort…
- Trial name
- NCT06806033
- Testing
- Obinutuzumab, Glofitamab, Gemcitabine
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
- Trial name
- NCT05878184
- Testing
- SC291
- Where
- 10 sites in United States, Australia
- Volunteers
- 16 people
- Sponsor
- Sana Biotechnology
Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
This I/II trial studies the side effects and best dose of lenalidomide when given together with nivolumab and to see how well they work in treating patients with non-Hodgkin or Hodgkin lymphoma that has come back and does not…
- Conditions
- Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma
- Trial name
- NCT03015896
- Testing
- Laboratory Biomarker Analysis, Lenalidomide, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- David Bond, MD
Lymphoma
A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
The researchers are doing this study to find out whether the combination of epcoritamab with tafasitamab and lenalidomide is a safe and effective treatment for relapsed or refractory DLBCL.
- Trial name
- ECLAT (NCT07030699)
- Testing
- Epcoritamab, Lenalidomide, Tafasitamab
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Collecting and Storing Blood Samples From Patients With Cancer
RATIONALE: Collecting and storing samples of blood from patients with cancer to test in the laboratory may help the study of cancer in the future.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00900120
- Sponsor
- University of Medicine and Dentistry of New Jersey
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma
Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
This phase I/II trial is studying the side effects and best dose of oblimersen when given together with rituximab and combination chemotherapy and to see how well they work in treating patients with relapsed or refractory…
- Conditions
- Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma
- Trial name
- NCT00086944
- Testing
- oblimersen sodium, rituximab, ifosfamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Childhood Langerhans Cell Histiocytosis, Leukemia
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
RATIONALE: Umbilical cord blood or placental blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells.
- Conditions
- Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00008164
- Testing
- umbilical cord blood transplantation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Graft Versus Host Disease, Leukemia
Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders
RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and cyclophosphamide, together with antithymocyte globulin before a donor stem cell transplant helps stop the growth of cancer and abnormal cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00740467
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Institut Paoli-Calmettes
Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma
The purpose of this study is to evaluate the safety and optimal dose of PCAR-119 in patients who are going to receive stem cell transplantation but without available treatment to achieve complete remission prior to the transplant.
- Conditions
- Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT02892695
- Testing
- anti-CD19 CAR-NK cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Relapsed Follicular Lymphoma
A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)
This is a Phase III, multicenter, open-label, randomized and controlled study to compare the efficacy of a consolidation therapy with RIT versus ASCT in patients with FL in CR or PR after second or third line chemotherapy…
- Trial name
- NCT01827605
- Testing
- ZEVALIN, BEAM
- Where
- 38 sites in Italy
- Volunteers
- 159 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Relapsed/Refractory Follicular Lymphoma
IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma
This study is a randomized, controlled, double-blind, multicenter, phase III clinical study to evaluate the efficacy of IMM0306 (Amulirafusp Alfa)in combination with lenalidomide versus placebo in combination with lenalidomide in…
- Trial name
- NCT07355283
- Testing
- IMM0306 2.0 mg/kg, Lenalidomide 20 mg
- Where
- China
- Volunteers
- 198 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Lymphoma
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
The study will evaluate the progression-free survival benefit of duvelisib monotherapy as compared to investigator's choice of gemcitabine or bendamustine in participants with relapsed/refractory nodal T cell lymphoma with TFH…
- Trial name
- TERZO (NCT06522737)
- Testing
- Duvelisib, Gemcitabine, Bendamustine
- Where
- 44 sites in Belgium, Czechia and 8 more
- Volunteers
- 124 people
- Sponsor
- SecuraBio
Follicular Lymphoma, Lymphoma
Epco, Zanu, Ritux for R/R FL or MZL
The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory Follicular Lymphoma (FL) or marginal zone…
- Conditions
- Follicular Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Relapsed Lymphoma
- Trial name
- NCT06563596
- Testing
- Zanubrutinib, Rituximab, Epcoritamab
- Where
- 3 sites in United States
- Volunteers
- 71 people
- Sponsor
- Reid Merryman, MD
Diffuse Large B Cell Lymphoma, Follicular Lymphoma
A Trial of Radiotherapy and Durvalumab in DLBCL and FL
The primary objective for this study is to determine the safety profile of radiotherapy and durvalumab, a PD-L1 inhibitor. Primary endpoint: Toxicity, drug pharmacokinetics (PK), maximum tolerated dose (MTD) and recommended phase…
- Trial name
- RaDD (NCT03610061)
- Testing
- Durvalumab, Radiotherapy, Radiotherapy (cohort 6 only)
- Where
- 3 sites in Australia
- Volunteers
- 34 people
- Sponsor
- Austin Health
Non-Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL
This research study is evaluating a drug called carfilzomib used in combination with another drug called belinostat with participants who have relapsed or refractory non-Hodgkin lymphoma (NHL).
- Conditions
- Non-Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT02142530
- Testing
- Carfilzomib, Belinostat
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts General Hospital
Lymphoma, Non-Hodgkin
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-cell NHL.
- Trial name
- MAGNIFY (NCT01996865)
- Testing
- Lenalidomide, Rituximab
- Where
- 126 sites in United States, Germany and 1 more
- Volunteers
- 503 people
- Sponsor
- Celgene
Cancer
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
RATIONALE: White blood cells that have been treated in the laboratory may kill cells that are infected with cytomegalovirus. PURPOSE: This phase I trial is studying how well cytotoxic T cells work in treating patients who have…
- Trial name
- NCT00769613
- Testing
- cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Milton S. Hershey Medical Center
Leukemia, Lymphoma
Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Monoclonal antibodies such as daclizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00006350
- Testing
- daclizumab, therapeutic allogeneic lymphocytes, mycophenolate mofetil
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Follicular Lymphoma, Marginal Zone Lymphoma
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Oral clofarabine is related to two intravenous chemotherapy drugs used for this disease and works in two different ways. It affects the development of new cancer cells by blocking two enzymes that cancer cells need to reproduce.
- Conditions
- Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT00644189
- Testing
- Clofarabine
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Relapsed
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies
This is an open-label Phase 1 study to determine the feasibility, safety, and the recommended maximum tolerated Dose (MTD) of a single infusion of RPM CD19 mbIL15 CAR-T cells for adult patients.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Primary Mediastinal Large B Cell Lymphoma
- Trial name
- NCT04844086
- Testing
- RPM CD19-mbIL15-CAR-T cells
- Where
- Taiwan
- Volunteers
- 2 people
- Sponsor
- Eden BioCell Ltd.